Report from Europe - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Report from Europe
The European Commission and Medicines Agency seem to be moving in advance of their ICH partners to update standards.

Pharmaceutical Technology
Volume 35, Issue 1, pp. 18, 20

Because the ICH guidelines cover individual aspects of pharmaceutical manufacture, there is no uniform single ICH guideline for GMP for finished products, according to EMA. That said, "....there is pre-existing broad equivalence in requirements," says the EMA spokesperson. "We are in regular contact with our US and Japanese colleagues under different frameworks and do not believe that the changes proposed are inconsistent with existing or planned requirements of those international partners."

Nonetheless, the divergences are beginning to concern manufacturers of medicines and APIs. "In general, we always advocate that requirements should be harmonized between geographic areas as much as possible," says Chris Oldenhof, president of the Active Pharmaceutical Ingredients Committee (APIC), a branch of the European Chemical Industry Council.

API producers in Europe are also worried that the scope of the alterations on starting materials could be too broad to be effective. "If the required changes are to apply further upstream to include raw and starting materials throughout the synthesis chain then they will not be realistic," says Oldenhof, who is also manager of external regulatory affairs at DSM (Heerlen, The Netherlands). "It is well-known that unrealistic requirements usually lead to widespread noncompliance and even fraud."

The European Commission has declined to amend the EU guideline to allow for mandatory GMP inspections by regulatory agencies of API plants, which has been a long-established demand of European API producers. "Without adequate plant inspections, levels of compliance will always be quite low," says Oldenhof. "This is the main weakness of the proposals."

For APIC and the European Fine Chemicals Group, which also represents API producers, the Commission's suggested changes are welcome overall because they tighten up existing GMP controls in an area in which it is notoriously difficult to enforce regulations.

Sean Milmo is a freelance writer based in Essex, UK.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here